Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 7, 2008, Pages 842-848

  Garcia Vilela, Eduardo ^a   De Lourdes De Abreu Ferrari, Maria ^a   Oswaldo Da Gama Torres, Henrique ^a   Guerra Pinto, Ademar ^a   Carolina Carneiro Aguirre, Ana ^a   Paiva Martins, Fabiana ^a   Marcos Andrade Goulart, Eugenio ^a   Sales Da Cunha, Aloisio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Crohn's disease; Intestinal permeability; Probiotics

Indexed keywords

AZATHIOPRINE; CELLULOSE; FLORATIL; LACTULOSE; MAGNESIUM STEARATE; MANNITOL; MESALAZINE; METRONIDAZOLE; PLACEBO; PREDNISONE; PROBIOTIC AGENT; SACCHAROMYCES BOULARDII EXTRACT; SUCROSE; THALIDOMIDE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; FEMALE; HUMAN; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERMEABILITY TEST; LACTULOSE MANNITOL RATIO; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SACCHAROMYCES BOULARDII; TREATMENT OUTCOME; VOMITING;

ADULT; CROHN DISEASE; FEMALE; HUMANS; INTESTINAL MUCOSA; LACTULOSE; MALE; MANNITOL; MIDDLE AGED; PERMEABILITY; PROBIOTICS; REMISSION INDUCTION; SACCHAROMYCES;

EID: 46349091181     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520801943354     Document Type: Article

References (36)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic fator. Ann Intern Med 1986;105:883-5.
3. Katz KD, Hollander D, Vadheim C, McElrie C, Delahunty T, Dadufalza UD, et al. Intestinal permeability in patients with Crohn's disease and their relatives. Gastroenterology 1989;97:927-31.
4. Hollander D. Crohn's disease, TNF-α, and the leaky gut. The chicken or the egg? Am J Gastroenterol 2002;97:1867-8.
5. Rutgeerts P, Ghoos Y, Van Trappen E, Eyssen H. Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 1981;11:199-206.
6. Bengmark S. Ecological control of the gastrointestinal tract. The role of probiota flora. Gut 1998;42:2-7.
7. Spirt MJ. Antibiotics in inflammatory bowel disease: new choices for an old disease. Am J Gastroenterol 1994;89:974-8.
8. Chiodini RJ. Antimicrobial agents and Crohn's disease: do they have a therapeutic role? Ital J Gastroenterol Hepatol 1998;30:593-8.
9. Bjarnason I, MacPherson AJ, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
10. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci 1992;82:471-88.
11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976;70:439-44.
12. Gasche C, Scholmerich J, Brinskov J, D'Haens G, Hanauer SB, Irvine EJ. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
13. Wyatt J, Volgelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
14. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, et al. Intestinal permeability test as a predictor of clinical in Crohn's disease. Am J Gastroenterol 1999;94:2956-60.
15. Secondulfo M, Iafusco D, Canatu R, deMagistris L, Sapone A, Generoso M, et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 2004;36:35-45.
16. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the fecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-84.
17. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeers P. early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
18. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
19. Cartun RW, Van Kruiningen HJ, Pedersen CA, Bermen MM. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993;6:212-9.
20. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosa flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
21. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
22. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol 2003;38:9-12.
23. Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006;12:5941-50.
24. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-9.
25. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988-97.
26. a cells. Am J Gastroenterol 2002;97:1182-6.
27. Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989;10:353-64.
28. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006;131:1812-25.
29. Buts J-P, De Keyser N, Marandi N, Hermans D, Sokal EM, Chae YH, et al. Saccharomyces boulardii upgrades cellular adaptation after enterectomy in rats. Gut 1999;45:89-96.
30. Buts J-P, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006;51:1485-92.
31. Ricci G, Stabellini G, Bersani G, Marangoni G, Fabbri P, Gentili G, et al. Ornithine decarboxylase in colonic mucosa from patients with moderate or severe Crohn's disease and ulcerative colitis. Eur J Gastroenterol Hepatol 1999;11:903-4.
32. Allgayer H, Roisch U, Zehnter E, Ziegenhagen DJ, Dienes HP, Kruis W. Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Dig Dis Sci 2007;52:25-30.
33. Rijnders BJ, Van Wijngaerden E, Verwaert C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000;26:825.
34. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993;31:129-34.
35. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
36. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG hepful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-7.